OLATHE, Kansas — Ronawk, innovators in stem cell expansion technologies, has launched a trial program to provide its patented tissue-blocks (T-Blocks) to commercial cell producers and regenerative medicine partners. Their T-Blocks are a 3D matrix consumable product that enable the stem cell industry by providing means to increase stem cell production by 3,600 times vs. traditional expansion methods. [Read more…]
Three New COVID-19 Patients Treated with Zofin(TM) Report Improvement
Organicell Commences Phase I/II Clinical Trial Enrollment
Miami, FL (September 2, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat two mild to moderate COVID-19 patients and one “Long Hauler” post COVID-19 patient. [Read more…]
denovoMATRIX GmbH on the path to enabling cell-based therapies
Now awarded ISO 9001:2015 Certification for Quality Management System
As an organization, denovoMATRIX is driven by the undertaking of continuous improvement of our quality management system, a commitment to unremitting development of our staff and the fostering of customer relationships. denovoMATRIX GmbH is pleased to announce its ISO 9001:2015 Quality Management Standard certification by TÜV Süd. [Read more…]
FDA Clears Jointechlabs’ MiniTC for Point-of-Care Fat Tissue Processing and its Broad Range of Applications
San Francisco, CA – August 26, 2020 – Jointechlabs – a leader in point-of-care regenerative medicine therapies – today announced that the U.S. Food and Drug Administration (FDA) cleared the company’s MiniTCTM for point-of-care fat tissue processing designed to obtain microfat (or fat grafts), for multiple indications. Jointechlabs plans to focus on a range of therapeutic areas including medical aesthetics, plastic surgery, orthobiologics and wound healing. [Read more…]
Organicell Phase I/II Clinical Trial Update
Lead Therapeutic Candidate To Be Named Zofin(TM)
Miami, FL (August 18, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has partnered with Alternative Research Associates, LLC and Larkin Hospital in Miami, FL to initiate a randomized, double-blinded, placebo-controlled phase I/II clinical trial against COVID-19 of its lead therapeutic candidate, which has been rebranded as Zofin. [Read more…]
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 117
- Next Page »